ANDA 91128, held by Hikma Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 91128 (Montelukast Sodium), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 3, 2012, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Jan 24, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 30, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 21, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 21, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 21, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 16, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters